HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat.

AbstractRATIONALE:
Activation of 5-HT2C receptors is thought to enhance satiety and to mediate the action of the prototypical anorectic drug d-fenfluramine.
OBJECTIVE:
Four experiments investigated the role of the 5-HT2C receptor in the modulation of feeding by comparison of the effects of the putative selective 5-HT2C receptor agonist Ro 60-0175 and d-fenfluramine on feeding behaviour.
METHODS:
Microstructural analyses of meal patterning and drinking of a palatable solution were made over a range of drug doses administered to male Lister hooded rats.
RESULTS:
Ro 60-0175 increased the latency to the first meal (3 mg/kg) and reduced meal size (1 mg/kg). d-Fenfluramine (1 mg/kg) produced a similar behavioural pattern, but 3 mg/kg produced a more profound hypophagia that persisted for 10-12 h. Ro 60-0175 (1, 3 mg/kg) and d-fenfluramine (1.5 mg/kg) reduced ingestion of a palatable glucose/saccharin solution, by a reduction in the number of bouts of licking, with little effect on the size of individual bouts. d-Fenfluramine-induced hypophagia (2.1 mg/kg) was challenged by the administration of the selective 5-HT2C receptor antagonist SB 242084 (1, 3 mg/kg) in the meal patterning paradigm. SB 242084 significantly attenuated the decrease in feeding rate and increase in latency to feed produced by d-fenfluramine, but had no effect on the fenfluramine-induced reduction in meal size. A similar pattern of results was obtained when Ro 60-0175-induced hypophagia (3 mg/kg) was challenged by SB 242084 (1, 3 mg/kg).
CONCLUSIONS:
These results demonstrate that Ro 60-0175 is a useful probe of the importance of 5-HT2C activation in the control of food intake and support the hypothesis that activation of 5-HT2C receptors is a critical aspect of the hypophagic action of d-fenfluramine. The 5-HT2C receptor may prove to be a useful target in the development of clinically effective drugs for the treatment of obesity.
AuthorsP G Clifton, M D Lee, C T Dourish
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 152 Issue 3 Pg. 256-67 (Oct 2000) ISSN: 0033-3158 [Print] Germany
PMID11105935 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 6-chloro-5-methyl-1-((2-(2-methylpyrid-3-yloxy)pyrid-5-yl)carbamoyl)indoline
  • Aminopyridines
  • Ethylamines
  • Indoles
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin
  • Ro 60-0175
  • Serotonin Receptor Agonists
  • Fenfluramine
Topics
  • Aminopyridines (pharmacology)
  • Animals
  • Dose-Response Relationship, Drug
  • Ethylamines (pharmacology)
  • Feeding Behavior (drug effects)
  • Fenfluramine (pharmacology)
  • Indoles (pharmacology)
  • Male
  • Rats
  • Receptor, Serotonin, 5-HT2C
  • Receptors, Serotonin (drug effects)
  • Serotonin Receptor Agonists (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: